Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Development of a Single Shot, Neonatal Pertussis Vaccine
EF 2009-10
Résumé
Whooping cough (pertussis) is a highly contagious disease caused by infection with Bordetella pertussis (Bp). Bp can infect individuals of all ages but symptoms and disease are most severe in newborns and infants. Current pertussis vaccines are only given from 2 months onwards, and induce full protection only after multiple boosters, leaving the young infant unprotected for most of the first year of life. Current vaccines also do not elicit long-term protection, resulting in reinfection of older individuals; these reinfected individuals infect the unprotected infants, creating a resurgence of whooping cough cases in recent years, especially in the developing world. Thus, there is an urgent need to formulate a vaccine that can protect infants most susceptible to Bp infection very early in life and induce life-long protection. Studies have shown that newborns are able to generate a robust immune response against vaccines when delivered in an appropriate manner. We have shown that a weakened (attenuated) strain of Listeria monocytogenes (Lm) can be safely used as a vaccine vehicle able to elicit a broad spectrum of protective immune responses in newborn mice. Importantly, our Lm strains can elicit immediate and life-long protection after just a single immunization given at birth. Moreover, our Lm vaccine platform would not require refrigeration and can be given by mouth, making it an attractive vehicle for new pertussis vaccines especially for developing countries. Lastly, attenuated Lm is known to be safe in humans, and able to elicit strong immune responses to vaccines it delivers. We propose that use of our attenuated Lm strains as neonatal Bp vaccine vehicles will provide the single shot vaccine against Bp that can confer immediate and life-long protection after only one dose given at birth.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201561
Name
Wee Kathleen L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Development of a Single Shot, Neonatal Pertussis Vaccine
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunity; Immunization; Infectious Disease; Mouse Model; Pertussis; Vaccine; Whooping Cough
Abstract
Whooping cough (pertussis) is a highly contagious disease caused by infection with Bordetella pertussis (Bp). Bp can infect individuals of all ages but symptoms and disease are most severe in newborns and infants. Current pertussis vaccines are only given from 2 months onwards, and induce full protection only after multiple boosters, leaving the young infant unprotected for most of the first year of life. Current vaccines also do not elicit long-term protection, resulting in reinfection of older individuals; these reinfected individuals infect the unprotected infants, creating a resurgence of whooping cough cases in recent years, especially in the developing world. Thus, there is an urgent need to formulate a vaccine that can protect infants most susceptible to Bp infection very early in life and induce life-long protection. Studies have shown that newborns are able to generate a robust immune response against vaccines when delivered in an appropriate manner. We have shown that a weakened (attenuated) strain of Listeria monocytogenes (Lm) can be safely used as a vaccine vehicle able to elicit a broad spectrum of protective immune responses in newborn mice. Importantly, our Lm strains can elicit immediate and life-long protection after just a single immunization given at birth. Moreover, our Lm vaccine platform would not require refrigeration and can be given by mouth, making it an attractive vehicle for new pertussis vaccines especially for developing countries. Lastly, attenuated Lm is known to be safe in humans, and able to elicit strong immune responses to vaccines it delivers. We propose that use of our attenuated Lm strains as neonatal Bp vaccine vehicles will provide the single shot vaccine against Bp that can confer immediate and life-long protection after only one dose given at birth.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wee, Kathleen L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~